Trial Profile
A Postmarketing Clinical Study of Repaglinide in Combination with Insulin in Patients with Type 2 Diabetes Mellitus
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Repaglinide (Primary) ; Insulin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Sumitomo Pharma
- 10 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 03 Jun 2016 New trial record